AU2001294602A1 - Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia - Google Patents

Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia

Info

Publication number
AU2001294602A1
AU2001294602A1 AU2001294602A AU9460201A AU2001294602A1 AU 2001294602 A1 AU2001294602 A1 AU 2001294602A1 AU 2001294602 A AU2001294602 A AU 2001294602A AU 9460201 A AU9460201 A AU 9460201A AU 2001294602 A1 AU2001294602 A1 AU 2001294602A1
Authority
AU
Australia
Prior art keywords
reduction
conjugated fatty
treatment
hyperglycemia
body fat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294602A
Inventor
Danielle Greenberg
David P. Katz
James R. Komorowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutrition 21 LLC
Original Assignee
Nutrition 21 LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutrition 21 LLC filed Critical Nutrition 21 LLC
Publication of AU2001294602A1 publication Critical patent/AU2001294602A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/76—Salicaceae (Willow family), e.g. poplar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Abstract

A composition for treating insulin-dependent diabetes, reducing body fat, improving insulin sensitivity, reducing hyperglycemia, and reducing hypercholesterolemia with at least one chromium complex and a conjugated fatty acid or conjugated fatty alcohol is disclosed. A method of treating a subject suffering from insulin-dependent diabetes by administering a composition that includes at least one chromium complex and a conjugated fatty acid or conjugated fatty alcohol is similarly provided. The administration of a composition containing an effective dose of at least one chromium complex and a conjugated fatty acid or conjugated fatty alcohol for the treatment of obesity is likewise provided.
AU2001294602A 2000-09-21 2001-09-20 Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia Abandoned AU2001294602A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23447400P 2000-09-21 2000-09-21
US60/234,474 2000-09-21
US29668801P 2001-06-06 2001-06-06
US60/296,688 2001-06-06
PCT/US2001/029422 WO2002024180A2 (en) 2000-09-21 2001-09-20 Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia

Publications (1)

Publication Number Publication Date
AU2001294602A1 true AU2001294602A1 (en) 2002-04-02

Family

ID=26927971

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294602A Abandoned AU2001294602A1 (en) 2000-09-21 2001-09-20 Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia

Country Status (9)

Country Link
US (4) US6809115B2 (en)
EP (1) EP1357977B1 (en)
JP (1) JP2004509143A (en)
CN (1) CN1665566A (en)
AT (1) ATE271406T1 (en)
AU (1) AU2001294602A1 (en)
DE (1) DE60104450T2 (en)
ES (1) ES2223924T3 (en)
WO (1) WO2002024180A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927636B1 (en) 1997-07-14 2011-04-19 Interhealth Nutraceuticals, Inc. Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight
US20030228347A1 (en) * 2000-09-12 2003-12-11 Clark George H. Amino acid chelate for the effective supplementation of calcium magnesium and potassium in the human diet
US20040157929A1 (en) * 2002-04-01 2004-08-12 Ohia Sunny E. Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof
CA2448241A1 (en) * 2001-05-31 2002-12-05 Wisconsin Alumni Research Foundation Conjugated nonadecadienoic acid compositions
US7119110B2 (en) * 2001-10-05 2006-10-10 Interhealth Nutraceuticals Incorporated Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
US6888016B2 (en) * 2001-10-16 2005-05-03 Loders Croklaan Usa Llc Mixtures for stimulating glucose up-take
US20030119913A1 (en) * 2001-12-20 2003-06-26 Ohia Sunny E. Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof
US6974592B2 (en) 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
DE10226018A1 (en) * 2002-06-12 2003-12-24 Cognis Deutschland Gmbh Preparations with conjugated linoleic alcohol
BR0312537A (en) * 2002-07-01 2005-04-19 Unilever Nv Uses of whey protein hydrolyzate in edible composition, satiety induction method in humans or animals and method of improving or controlling body image perception and / or body weight control and / or calorie intake control and / or / or aid in adhering to a diet plan
KR100523446B1 (en) * 2002-08-23 2005-10-25 주식회사 엠디바이오알파 Frankinsence extracts having activatory effects on 5' AMP-activated protin kinase
IL152397A (en) * 2002-10-21 2009-02-11 Hadasit Med Res Service Compositions and compounds for the treatment of hyperglycemia
CA2471821C (en) * 2002-11-04 2006-04-25 Ocean Nutrition Canada Limited Microcapsules having multiple shells and method for the preparation thereof
EP1571925A1 (en) * 2002-12-20 2005-09-14 Unilever N.V. Blood glucose regulating composition
US7759507B2 (en) * 2003-09-05 2010-07-20 Abbott Laboratories Lipid system and methods of use
TW200518768A (en) * 2003-11-17 2005-06-16 Pepgen Corp Methods for treatment of obesity and for promotion of weight loss
US20060029642A1 (en) 2004-08-03 2006-02-09 Dusan Miljkovic Methods and compositions for improved chromium complexes
US7297686B2 (en) * 2004-11-16 2007-11-20 Hwang David L Chromium complex with insulin-like activity
GB0426264D0 (en) * 2004-11-30 2004-12-29 Trigen Ltd Compounds
US8034450B2 (en) * 2005-01-21 2011-10-11 Ocean Nutrition Canada Limited Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof
US20080139649A1 (en) * 2005-01-27 2008-06-12 Barrow Colin J Fatty Acid-Benzenediol Derivatives and Methods of Making and Using Thereof
WO2006109194A2 (en) * 2005-01-27 2006-10-19 Ocean Nutrition Canada Ltd. Chromium-fatty acid compounds and methods of making and using thereof
GB0514463D0 (en) 2005-01-31 2005-08-17 Loders Croklaan Bv Use of pinolenic acid
US9968120B2 (en) * 2006-05-17 2018-05-15 Dsm Nutritional Products Ag Homogenized formulations containing microcapsules and methods of making and using thereof
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
WO2007109845A1 (en) * 2006-03-28 2007-10-04 Medical Therapies Limited Prophylaxis or treatment of diabetes
US20100055281A1 (en) * 2006-04-07 2010-03-04 Ocean Nutrition Canada Limited Emulsions and Microcapsules With Substances Having Low Interfacial Tension, Methods of Making and Using Thereof
CA2650342C (en) * 2006-04-26 2014-09-16 Mandrillus Pharma, Llc Chromium complexes
NZ573327A (en) 2006-06-05 2012-07-27 Ocean Nutrition Canada Ltd Microcapsules with improved shells
JP5045879B2 (en) * 2006-06-07 2012-10-10 株式会社龍泉堂 A mixture having an effect of improving insulin resistance, an effect of suppressing weight gain, and an effect of preventing and improving fatty liver
US20090203780A1 (en) * 2006-06-27 2009-08-13 Luisa Gambelli Use of a Polyunsaturated Fatty Acid Compound
KR20090077081A (en) * 2006-11-03 2009-07-14 프로노바 바이오파마 노르지 에이에스 Fatty acid alcohols
WO2008085997A2 (en) 2007-01-10 2008-07-17 Ocean Nutrition Canada, Ltd. Vegetarian microcapsules
CA3021932C (en) * 2007-01-31 2020-12-15 Jds Therapeutics, Llc Use of chromium histidinate for treatment of cardiometabolic disorders
ITPD20070049A1 (en) * 2007-02-14 2008-08-15 Sila S R L CONJUGATED LINOLEIC ACID PRODUCT AND PROCESS FOR ITS MANUFACTURE
PL2134351T3 (en) 2007-03-13 2017-10-31 Jds Therapeutics Llc Methods and compositions for the sustained release of chromium
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
JP2010202634A (en) * 2008-06-05 2010-09-16 Green Kanpo Seiyaku Kk Crude drug-containing composition and use thereof
TWI454221B (en) * 2008-07-14 2014-10-01 Composition and method for inhibiting formation of body fat
WO2010105239A1 (en) * 2009-03-13 2010-09-16 Russell Kenneth O Method for enhancing insulin mediated uptake of nutrients into cells
EP3513790A1 (en) * 2009-07-01 2019-07-24 JDS Therapeutics, LLC Chromium complexes as enhancers of brain glucose transporters
WO2012087742A2 (en) * 2010-12-21 2012-06-28 Nestec S.A. Methods and compositions suitable for managing blood glucose in animals
EP4070801A1 (en) * 2011-03-01 2022-10-12 Nutrition 21, LLC Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
US20130344007A1 (en) * 2012-06-26 2013-12-26 Yl Holdings, Inc. Frankincense chewing gum
CN103082298B (en) * 2013-01-17 2014-08-13 吉林省中药制剂工程研究中心有限公司 Health-care food for reducing blood glucose in assisted mode and preparation method thereof
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
CA2990230A1 (en) 2015-06-19 2016-12-22 University Of Southern California Compositions and methods for modified nutrient delivery
EA031455B1 (en) * 2015-08-03 2019-01-31 Республиканское Государственное Предприятие На Праве Хозяйственного Ведения "Северо-Казахстанский Государственный Университет Имени Манаша Козыбаева" Emulsion medicinal product
CA3014308A1 (en) * 2016-02-11 2017-08-17 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
ES2944572T3 (en) * 2016-03-15 2023-06-22 Univ London Queen Mary Obesity treatment procedure
US10820617B1 (en) 2018-03-29 2020-11-03 Government Of The United States, As Represented By The Secretary Of The Air Force All inclusive electrolytes, vitamins, and protein powder training supplement
CN111568889A (en) * 2020-06-12 2020-08-25 四川大学华西医院 Application of hydroxyoctadecadienoic acid in preparation of alpha-glucosidase inhibitor drugs and separation method thereof
CN115245510A (en) * 2021-04-28 2022-10-28 扬州大学 Application of trans-10, cis-12 conjugated linoleic acid

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248607A1 (en) * 1972-10-04 1974-04-11 Wacker Chemie Gmbh METHOD FOR PRODUCING POLYVINYL HALOGENIDES
US3899476A (en) 1974-04-29 1975-08-12 Westvaco Corp Process for making a methacrylic acid adduct of linoleic acid and product
US3923768A (en) 1974-11-18 1975-12-02 Westvaco Corp Treatment of tall oil fatty acids
US4056637A (en) 1976-06-08 1977-11-01 Japan Natural Food Co. Ltd. Process for preparing food products containing a lactic acid bacteria-fermented product of a cereal germ
FR2474310A1 (en) 1980-01-25 1981-07-31 Oreal STABLE SOLUTION WITH OXIDATION OF VITAMIN F AND JOJOBA OIL AND COSMETIC COMPOSITIONS CONTAINING THE SAME
USRE33988E (en) 1980-08-08 1992-07-07 The United States of America as repesented by the Secretary of Agriculture Dietary supplementation with essential metal picolinates
FR2490631A1 (en) 1980-09-24 1982-03-26 Roussel Uclaf NOVEL LIPID COMPOSITION FOR USE IN DIETETICS, REANIMATION AND THERAPEUTICS
US4954492A (en) 1983-07-08 1990-09-04 The William Seroy Group Synthetic GTF chromium material for decreasing blood lipid levels and process therefor
US5194615A (en) 1983-07-08 1993-03-16 The William Seroy Group Synthetic GTF chromium nicotinate material and its preparation
US4871768A (en) 1984-07-12 1989-10-03 New England Deaconess Hospital Corporation Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
US5175156A (en) 1987-11-30 1992-12-29 Nutrition 21 Chromic picolinate treatment
US5087623A (en) 1988-05-31 1992-02-11 Nitrition 21 Chromic picolinate treatment
US5017614A (en) 1989-02-17 1991-05-21 Wisconsin Alumni Research Foundation Methods of preventing oxidation, quenching singlet oxygen and inhibiting mold growth and novel compositions therefor
US5070104A (en) 1989-02-17 1991-12-03 Wisconsin Alumni Research Foundation Methods of chelating metal and novel compositions therefor
US5208356A (en) 1989-02-17 1993-05-04 Wisconsin Alumni Research Foundation Octadecadienoic phospholipic esters, antioxidant and mold inhibiting compositions
US5087624A (en) 1989-03-21 1992-02-11 Nutrition 21 Chromic picolinate treatment
US5033534A (en) * 1990-03-02 1991-07-23 Nkk Corporation Method for continuous casting of steel
US5053534A (en) 1990-10-11 1991-10-01 Westvaco Corporation Process for making a dicarboxylic acid
US5194640A (en) 1991-06-10 1993-03-16 Westvaco Corporation Process for making high-purity oleic acid
US5554646A (en) 1992-04-29 1996-09-10 Wisconsin Alumni Research Foundation Method for reducing body fat in animals
US5430066A (en) 1992-04-29 1995-07-04 Wisconsin Alumni Research Foundation Methods for preventing weight loss, reduction in weight gain, and anorexia due to immune stimulation
US5674901A (en) * 1995-06-01 1997-10-07 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations
US5428072A (en) 1992-04-29 1995-06-27 Wisconsin Alumni Research Foundation Method of increasing the efficiency of feed conversion in animals
US5292538A (en) * 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
US5543405A (en) 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity
US5855949A (en) 1994-01-10 1999-01-05 Mclean; Linsey Dietary system high in oil intake
US5760082C1 (en) 1994-08-29 2001-03-06 Wisconsin Alumni Res Found Dietetic foods containing conjugated linoleic acids
US5814663A (en) 1994-08-29 1998-09-29 Wisconsin Alumni Research Foundation Method for maintaining an existing level of body fat
US5890905A (en) * 1995-01-20 1999-04-06 Bergman; Marilyn M. Educational and life skills organizer/memory aid
FR2729957B1 (en) 1995-01-31 1997-12-05 Maurel Sante ORGANOMETALLIC COMPLEXES BASED ON SITOSTEROLS AND ACYLGLYCEROLS AND PHARMACEUTICAL COMPOSITIONS AND DIETETIC PRODUCTS CONTAINING SAME.
US6329361B1 (en) 1995-05-12 2001-12-11 Nutrition 21 High-dose chromic picolinate treatment of type II diabetes
US5856149A (en) 1995-06-01 1999-01-05 Wisconsin Alumni Research Foundation Method of producing conjugated fatty acids
US5626849A (en) * 1995-06-07 1997-05-06 Reliv International, Inc. Weight loss composition for burning and reducing synthesis of fats
US6184009B1 (en) 1995-11-14 2001-02-06 Loders Croklaan B.V. Process for the preparation of materials with a high content of conjugated long chain polyunsaturated fatty acids
DE69615513T2 (en) 1995-11-14 2002-05-08 Unilever Nv Edible spread
US5804210A (en) 1996-08-07 1998-09-08 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein
US5866560A (en) * 1996-08-20 1999-02-02 Schering Ag 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
US5770247A (en) 1996-10-03 1998-06-23 Wisconsin Alumni Research Foundation Method of increasing the CLA content of cow's milK
JP3017108B2 (en) 1996-10-30 2000-03-06 リノール油脂株式会社 Method for producing conjugated linoleic acid
US5855917A (en) 1996-12-04 1999-01-05 Wisconsin Alumni Research Foundation Method for controlling body fat and/or body weight in animals and pharmaceutical compositions for use therein comprising 20-carbon conjugated unsaturated fatty acids
JP2001511153A (en) * 1997-02-04 2001-08-07 ブイ． コスバブ，ジョン Compositions and methods for prevention and treatment of vascular degenerative diseases
US5892074A (en) 1997-02-18 1999-04-06 Seidel; Michael C. Synthesis of conjugated linoleic acid (CLA)
US6153774A (en) 1997-02-18 2000-11-28 Seidel; Michael C. Silver ion chromatography of high purity conjugated linoleic acid (CLA)
US5837733A (en) 1997-02-26 1998-11-17 Wisconsin Alumni Research Foundation Method for reducing secetion of apolipoprotein B in animals by administering conjugated linoleic acid
US5851572A (en) 1997-04-25 1998-12-22 Wisconsin Alumni Research Foundation Method of increasing fat firmness and improving meat quality in animals with conjugated linolenic acid
US6060087A (en) 1997-04-25 2000-05-09 Wisconsin Alumni Research Foundation Method of increasing fat firmness and improving meat quality in animals
US5789401A (en) 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
JPH11209279A (en) 1998-01-05 1999-08-03 Natural Ltd As Method for decreasing body weight and treating obesity
US6042869A (en) 1998-02-20 2000-03-28 Natural Nutrition Ltd. Bulk animal feeds containing conjugated linoleic acid
US6020377A (en) 1998-03-13 2000-02-01 Kansas State University Research Foundation Modified tall oil supplemented diet for growing-finishing pigs
US6015833A (en) 1998-03-17 2000-01-18 Conlinco., Inc. Conjugated linoleic acid compositions
US6077525A (en) 1998-04-10 2000-06-20 The George Washington University Use of conjugated linoleic acids
US6113973A (en) 1998-04-15 2000-09-05 Wisconsin Alumni Research Foundation Eggs enriched with conjugated linoleic acid
US6177580B1 (en) 1998-04-21 2001-01-23 Henkel Kommanditgesellschaft Auf Aktien Conjugated linolenic acid-based synthetic triglycerides
US6132724A (en) * 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
US6060514A (en) 1998-05-04 2000-05-09 Conlin Co., Inc. Isomer enriched conjugated linoleic acid compositions
EP0954983B1 (en) 1998-05-04 2007-07-11 Natural ASA Methods of using isomer enriched conjugated linoleic acid compositions
US6214372B1 (en) 1998-05-04 2001-04-10 Con Lin Co., Inc. Method of using isomer enriched conjugated linoleic acid compositions
FI111513B (en) 1998-05-06 2003-08-15 Raisio Benecol Oy Novel compositions of phytosterol and phytostanol fatty acid esters, products containing them and processes for their preparation
US5948772A (en) * 1998-08-28 1999-09-07 Ambi Inc. Chromium picolinate compositions and uses thereof
US5980905A (en) * 1998-08-28 1999-11-09 Ambi Inc. Chromium polynicotinate compositions and uses thereof
AU5802499A (en) * 1998-09-01 2000-03-21 Amway Corporation Diet composition and method of weight management
US6019874A (en) 1999-01-19 2000-02-01 Berg; Lloyd Separation of conjugated linoleic acids by azeotropic distillation
US6020378A (en) 1999-03-30 2000-02-01 Wisconsin Alumni Research Foundation Method for selectively altering body fat level, feed efficiently, or weight gain
US6342619B2 (en) * 1999-04-01 2002-01-29 Michael C. Seidel Synthesis of conjugated fatty acid
US6541026B2 (en) * 1999-12-16 2003-04-01 Harry J. Siskind Nutritional composition, methods of producing said composition and methods of using said composition
WO2002009692A1 (en) 2000-08-02 2002-02-07 Pharmanutrients Methods and compositions for the attenuation and/or prevention of stress/catabolic responses
EP1305018A4 (en) 2000-08-02 2006-08-30 Pharmanutrients Method and compositions for prevention and/or treatment of diabetes and glucose modulation
WO2002009691A1 (en) 2000-08-02 2002-02-07 Pharmanutrients Methods and compositions for the prevention and treatment of syndrome x
WO2002009725A1 (en) 2000-08-02 2002-02-07 Pharmanutrients Methods and compositions for the prevention and treatment of inflamation, osteoarthritis, and other degenerative joint diseases

Also Published As

Publication number Publication date
US20090060941A9 (en) 2009-03-05
ATE271406T1 (en) 2004-08-15
CN1665566A (en) 2005-09-07
JP2004509143A (en) 2004-03-25
DE60104450T2 (en) 2005-09-15
ES2223924T3 (en) 2005-03-01
US20030091654A1 (en) 2003-05-15
WO2002024180A3 (en) 2003-04-24
US6809115B2 (en) 2004-10-26
EP1357977A2 (en) 2003-11-05
EP1357977B1 (en) 2004-07-21
US20090136539A9 (en) 2009-05-28
DE60104450D1 (en) 2004-08-26
WO2002024180A2 (en) 2002-03-28
US20060204518A1 (en) 2006-09-14
US20020081315A1 (en) 2002-06-27
US20060204517A1 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
AU2001294602A1 (en) Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia
AP2001002027A0 (en) Glucagon-like peptide -1 improves B-cell response to glucose in subjects with impaired glucose tolerance.
NO20003051L (en) Method of administration of AspB28 human insulin
BRPI0207700B8 (en) mixture of monodisperse conjugates, pharmaceutical composition, and, use of a substantially monodisperse mixture of an insulin polypeptide-oligomer conjugate
TW371628B (en) Composition for treating condyloma acuminata
UA32636C2 (en) Method for reducing cholesterol content in human blood serum
SG149814A1 (en) Compositions and methods for treating diabetes
BR0015974A (en) Use of levetiracetam, pharmaceutical composition, use of a pharmaceutical composition and methods to treat a patient administered with an amount of at least one compound and a disease and to selectively potentiate the therapeutic effect of a compound
CA2373266A1 (en) Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
NO976063L (en) Procedure for the treatment of diabetes
EP0766966A3 (en) Method of treating insulin resistance
EP1174135A3 (en) Pharmaceutical composition for use in treatment of diabetes
AU7371600A (en) Use of alpha-linolenic acid metabolites for treatment or prevention of cancer
MY157727A (en) Administration of agents for the treatment of inflamation
AU9125798A (en) Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
AU2624400A (en) Monodisperse hexameric acylated insulin analog formulations
KR950007848A (en) Treatment of Anxiety with (S)-(-)-α-ethyl-2-oxo-1-pyrrolidineacetamide
KR950703353A (en) Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus
WO2003043569A3 (en) Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases
AU1795101A (en) Safety mechanism to prevent accidental patient injection and methods of same
GB0323979D0 (en) Therapeutic applications for c-peptide
WO2003032961A3 (en) Methods for preventing and treating bone loss with steroid compounds
AU6432899A (en) Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
WO1997005875A3 (en) A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
WO2001012166A3 (en) Improved treatment for acute physical insult to the central nervous system